HOXB7 has been explored as a potential target for overcoming resistance to L-OHP (oxaliplatin) in the treatment of GC, and results suggest that silencing HOXB7 can indeed restore L-OHP sensitivity (Yuan et al. 2020). This evidence concerns the gene HOXB7 and gastric cancer.